Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society
Advances in Therapy · 2025
DOI: 10.1007/s12325-025-03353-x ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Advances in Therapy, 2025. Verfasst von Paul Bastelica und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, IHU FOReSight, INSERM-DGOS CIC 1423, 75012, Paris, France. pbastelica…. Hauptthemen laut MEDLINE: Patient Preference, Glaucoma, Antihypertensive Agents. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Horus Pharma.
Abstract (Originalsprache)
INTRODUCTION: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists. METHODS: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma. The questionnaire collected data on demographics, treatment-related experiences, patient preferences, and the prioritization of six treatment criteria: cost, efficacy, dosing frequency, side effects, environmental impact, and ease of use. RESULTS: A total of 798 patients with glaucoma participated. There was no strong preference between multi-dose bottles and single-dose units (32.0% vs. 37.4%, respectively, with 29.2% of patients showing no preference). Side effects were reported by 31.8% of patients, and the use of artificial tears was significantly higher among those with longer treatment durations (31.3% for ≤ 2 years vs. 65.6% for > 20 years, p = 0.001). Notably, 63% of patients were unaware that their eye drops could contain preservatives. Regarding generics, 29.9% of patients had previously used one, while only 25.6% were willing to switch from their prescribed brand to a generic equivalent. Adherence was suboptimal, with only 66.2% of patients reporting being compliant. Younger age (p < 0.001) and lack of awareness about preservatives (p < 0.001) were significantly associated with non-adherence. When ranking treatment criteria, patients prioritized efficacy, followed by side effects, ease of use, cost, and environmental impact. CONCLUSION: This nationwide survey conducted by the French Glaucoma Society underscores the diversity of patient preferences and the critical need for personalized glaucoma care. A substantial proportion of patients feels insufficiently informed about preservatives and generics, which may negatively impact adherence. Enhanced patient education and individualized treatment strategies are essential for improving outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, IHU FOReSight, INSERM-DGOS CIC 1423, 75012, Paris, France. pbastelica@15-20.fr.
- Department of Ophthalmology, Ambroise Paré Hospital, AP-HP, University of Versailles Saint-Quentin-en-Yvelines, 78000, Versailles, France. pbastelica@15-20.fr.
- INSERM UMR 968, CNRS UMR 7210, Institut de La Vision, IHU FOReSIGHT, Sorbonne Université UM80, 75012, Paris, France. pbastelica@15-20.fr.
- Department of Ophthalmology III, Quinze-Vingts National Ophthalmology Hospital, IHU FOReSight, INSERM-DGOS CIC 1423, 75012, Paris, France.
- Department of Ophthalmology, Ambroise Paré Hospital, AP-HP, University of Versailles Saint-Quentin-en-Yvelines, 78000, Versailles, France.
- INSERM UMR 968, CNRS UMR 7210, Institut de La Vision, IHU FOReSIGHT, Sorbonne Université UM80, 75012, Paris, France.
Förderung
- Horus Pharma
Zitieren
APA
Bastelica, P., Labbe, A., Sahyoun, M., Baudouin, C., Lamirel, C., Poli, M., Renard, J. P., Rousseau, A., Schweitzer, C., & Aptel, F. (2025). Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society. Advances in Therapy. https://doi.org/10.1007/s12325-025-03353-x
Vancouver
Bastelica P, Labbe A, Sahyoun M, Baudouin C, Lamirel C, Poli M, et al. Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society. Advances in Therapy. 2025. doi:10.1007/s12325-025-03353-x
BibTeX
@article{Bastelica2025,
author = {Bastelica, Paul and Labbe, Antoine and Sahyoun, Marwan and Baudouin, Christophe and Lamirel, Cédric and Poli, Muriel and Renard, Jean-Paul and Rousseau, Antoine and Schweitzer, Cédric and Aptel, Florent},
title = {Patient Preferences and Understanding of Glaucoma Treatment: A Nationwide Survey by the French Glaucoma Society},
journal = {Advances in Therapy},
year = {2025},
doi = {10.1007/s12325-025-03353-x}
}
EUVIMED